219 related articles for article (PubMed ID: 37528266)
21. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
22. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
24. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
Al-Moghrabi N; Nofel A; Al-Yousef N; Madkhali S; Bin Amer SM; Alaiya A; Shinwari Z; Al-Tweigeri T; Karakas B; Tulbah A; Aboussekhra A
BMC Cancer; 2014 Nov; 14():830. PubMed ID: 25403427
[TBL] [Abstract][Full Text] [Related]
25. Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
Sun MY; Chang XZ; Xu GY; Dong Y; Zhou ZJ; Liu T; Wang CQ; Li YS
J Cancer Res Ther; 2018 Jun; 14(Supplement):S354-S361. PubMed ID: 29970689
[TBL] [Abstract][Full Text] [Related]
26. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
27. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
[TBL] [Abstract][Full Text] [Related]
29. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
Liu Y; Wang H; Wang X; Liu J; Li J; Wang X; Zhang Y; Bai Z; Zhou Q; Wu Y; Shen Y; Weng X; Liu F; Guo J; Di L; Gires O; Zhang Z; Chen Y; Wang H
J Hematol Oncol; 2021 Jan; 14(1):18. PubMed ID: 33461583
[TBL] [Abstract][Full Text] [Related]
32. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
[TBL] [Abstract][Full Text] [Related]
33. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
34. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
35. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
Abulkhair O; Al Balwi M; Makram O; Alsubaie L; Faris M; Shehata H; Hashim A; Arun B; Saadeddin A; Ibrahim E
J Glob Oncol; 2018 Aug; 4():1-9. PubMed ID: 30199306
[TBL] [Abstract][Full Text] [Related]
38. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
Moreno M; Oliveira JS; Brianese RC; de Castro DG; Sanches SM; Torrezan GT; Santiago KM; De Brot M; Cordeiro de Lima VC; Baroni Alves Makdissi F; Casali Da Rocha JC; Calsavara VF; Carraro DM
Cancer Med; 2023 Aug; 12(15):16129-16141. PubMed ID: 37485802
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
Paik HJ; Jung YJ; Kim DI; Lee S; Jung CS; Kang SK; Kim JJ; Oh SY; Joo JH; Kim HY
Oncology; 2021; 99(8):499-506. PubMed ID: 34098565
[TBL] [Abstract][Full Text] [Related]
40. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
